Calquence is designed to treat lymphoma but may reduce the inflammation caused by the coronavirus, which can trigger an extreme immune reaction called a cytokine storm that can be fatal.
The drug will be tested on hospitalized COVID-19 patients in a large randomized trial, with the first participants being recruited from the U.S. and Europe.
The drugmaker is hoping the drug could reduce the number of patients needed to be put on ventilators.
Read the full news release here.
More articles on pharmacy:
Johnson & Johnson warns of temporary Tylenol shortage
A breakdown of 6 of the most promising COVID-19 treatments
Employees test positive for COVID-19 at mail-order VA pharmacy in South Carolina
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
